▶ METHYLENE BLUE · SUBTOPIC · MECHANISM
METHYLENE BLUE Mechanism
For Laboratory Research Use Only. The mechanistic information below is descriptive of published research. No human dose is recommended. No clinical claim is made.
MECHANISM OF ACTION
Phenothiazine dye that acts as an alternative electron carrier in the mitochondrial electron-transport chain · accepts electrons at complex I and donates at cytochrome c, bypassing complex I/III dysfunction. FDA-approved for methemoglobinemia (Provayblue). Investigational in cognitive aging, ifosfamide-induced encephalopathy, and septic shock.
PHARMACOKINETIC HALF-LIFE
Reported half-life for METHYLENE BLUE: ~5-6 hours (oral / IV). Half-life determines the kinetic window across which receptor occupancy is maintained and frames the dosing rhythm used in published literature.
MECHANISM CATEGORIES
METHYLENE BLUE is tagged in 1 mechanism category on PEPPUDEX. Each category aggregates the broader pharmacology of related compounds.
Mitochondrial function encompasses oxidative phosphorylation, biogenesis (driven by PGC-1α), and quality-control processes (mitophagy). The mitochondrial-derived peptide MOTS-c regulates AMPK signaling and metabolic homeostasis. NAD+ supports the electron-transport chain and mitochondrial sirtuins (SIRT3, SIRT4, SIRT5).
MECHANISTIC OUTCOMES IN LITERATURE
The following outcomes are the mechanistic endpoints reported in the peer-reviewed literature, with PEPPUDEX evidence grades. Grades reflect study quality and replication, not clinical recommendation.
FDA-approved as Provayblue (IV 1-2 mg/kg) for acquired methemoglobinemia. Well-established clinical efficacy.
Wen 2011 (PMID 21357427) and adjacent studies characterize methylene blue as alternative electron acceptor at complex I / donor at cytochrome c, bypassing complex I/III dysfunction.
Small fMRI studies describe enhanced sustained attention. No completed Phase 3 cognitive trials.
Used in ifosfamide-induced encephalopathy. Limited published RCT evidence.
MECHANISM Q+A
▶ What is the half-life of methylene blue?
Approximately 5-6 hours plasma half-life for both oral and IV routes.
CITED LITERATURE
- Wen Y, Li W, Poteet EC, et al.. Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. J Biol Chem 2011. PMID 21357427. link
- Oz M, Lorke DE, Petroianu GA. Methylene blue and Alzheimer's disease. Biochem Pharmacol 2009. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-25